CSCs are also regarded as the seeds for therapeutic resistance, tumor recurrence and metastasis, and are recognized by a number of defined markers, such as they are positive for CD133 and CD44, and express high levels of integrin alpha2beta1 [13–17]. The gene discussed is PROM1; the disease is neoplasm.